FDA Approves First Oral PCSK9 Inhibitor - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 2 min

Share

Objective:

To report the FDA approval of enlicitide (LIPFENDRA) for reducing LDL cholesterol in adults with hypercholesterolemia.

Approach:
  • Approval Details: Enlicitide is approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
  • Mechanism of Action: Enlicitide is a macrocyclic peptide that binds PCSK9, inhibiting its interaction with LDL receptors.
  • Clinical Trials: The approval was supported by phase 3 CORALreef Lipids and CORALreef HeFH trials, which were randomized, double-blind, and placebo-controlled.
Key Findings:
  • Enlicitide produced a 56% placebo-adjusted reduction in LDL-C at week 24 in CORALreef Lipids.
  • In CORALreef HeFH, enlicitide resulted in a 59% placebo-adjusted reduction in LDL-C at week 24.
  • Reductions in non–high-density lipoprotein cholesterol and apolipoprotein B were observed in both trials.
  • Adverse reactions were similar between enlicitide and placebo groups, with diarrhea and dizziness reported.
Interpretation:

Limitations:
  • The long-term effects on cardiovascular morbidity and mortality are still under investigation.
Conclusion:

Enlicitide is the first oral PCSK9 inhibitor approved by the FDA, providing a new option for LDL cholesterol management.

Sources:

Original Source(s)

FDA Approves First Oral PCSK9 Inhibitor

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

Left ventricular longitudinal function and hyperkinetic profile: a new echo world to explore?

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.